Kexxtone 32.4g Continuous-Release Intraruminal Device Pack of 5

Target species Cattle (dairy cows and heifers) Indications for use, specifying the target species For the reduction in the incidence of ketosis in the peri-parturient dairy cow/heifer which is expected to develop ketosis. Contraindications Do not use in animals weighing less than 300 kg bodyweight. Do not use in cases of hypersensitivity to the active substance or to any of the excipients. Special warnings for each target species Identification of animals for treatment should be at veterinary discretion. Risk factors may include a history of energy-deficiency-related diseases, high body condition score and parity. In the event of early regurgitation, identify the animal by matching the animal ID number with the number on the intraruminal device and re-administer an undamaged intraruminal device (See Special Precautions). Special precautions for use Special precautions for use in animals Hold treated cattle in a confined area for 1 hour after administration to observe for failure to swallow or regurgitation. If this occurs re-administer the intraruminal device if undamaged. If damaged, administer a new intraruminal device. Recheck cattle for up to 4 days after dosing to observe for signs of an intraruminal device lodging in the oesophagus. Signs of lodging may include bloat which may be followed by coughing, drooling, inappetence and unthriftiness. Special precautions to be taken by the person administering the veterinary medicinal product to animals Exposure to the active substance may elicit an allergic response in susceptible individuals. People with known hypersensitivity to monensin or any of the excipients should avoid contact with the veterinary medicinal product. Do not eat, drink or smoke when handling the veterinary medicinal product. Use gloves when handling an intraruminal device, including during retrieval of a regurgitated intraruminal device. Remove gloves and wash hands and exposed skin after handling intraruminal devices. Other precautions Ingestion or oral exposure to monensin can be fatal in dogs, horses, other equines or guinea fowl. Do not allow dogs, horses, other equines or guinea fowl access to veterinary medicinal products containing monensin. Due to the risk of bolus regurgitation, do not allow these species access to areas where treated cattle have been kept. Adverse reactions (frequency and seriousness) In rare cases, digestive signs (e.g. diarrhoea, ruminant stomach disorder) have been observed. In very rare cases, oesophagus obstruction has been observed. The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s))- common (more than 1 but less than 10 animals in 100 animals treated)- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)- rare (more than 1 but less than 10 animals in 10,000 animals treated)- very rare (less than 1 animal in 10,000 animals treated, including isolated reports). Use during pregnancy, lactation or lay Can be used during pregnancy and lactation. Interaction with other medicinal products and other forms of interaction None known.
Vat Rate: 20%